Supplementary Figure S2 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

Figure S2. Comparison of CIR stratified by the different timepoint post treatment residual status either of plasma ctDNA (A-C) or mutation in BM (D-F). CIR according to residual status either of plasma ctDNA (A) or mutation in BM (D) at C2D1 post treatment; CIR according to residual status either of plasma ctDNA (B) or mutation in BM (E) at C3D1 post treatment; CIR according to residual status either of plasma ctDNA (C) or mutation in BM (F) at C4D1 post treatment. A higher CIR was associated with patients with ctDNA or BM DNA positive results at any point (all p<0.001). BM, bone marrow; CIR, cumulative incidence of relapse; C2D1, Cycle 2 day 1; C3D1, Cycle 3 day 1; C4D1, Cycle 4 day 1